CN103784481A - Method for extracting anti-tumor active component from Cordyceps militaris and application of active component - Google Patents
Method for extracting anti-tumor active component from Cordyceps militaris and application of active component Download PDFInfo
- Publication number
- CN103784481A CN103784481A CN201410040147.3A CN201410040147A CN103784481A CN 103784481 A CN103784481 A CN 103784481A CN 201410040147 A CN201410040147 A CN 201410040147A CN 103784481 A CN103784481 A CN 103784481A
- Authority
- CN
- China
- Prior art keywords
- component
- ethyl acetate
- elution
- isocratic elution
- hexane solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000000259 anti-tumor effect Effects 0.000 title claims abstract description 74
- 241001264174 Cordyceps militaris Species 0.000 title claims abstract description 56
- 238000000034 method Methods 0.000 title claims abstract description 35
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims abstract description 53
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims abstract description 51
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 claims abstract description 44
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims abstract description 28
- 238000010828 elution Methods 0.000 claims abstract description 27
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims abstract description 22
- SPWVRYZQLGQKGK-UHFFFAOYSA-N dichloromethane;hexane Chemical compound ClCCl.CCCCCC SPWVRYZQLGQKGK-UHFFFAOYSA-N 0.000 claims abstract description 15
- 239000000843 powder Substances 0.000 claims abstract description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 12
- 239000002246 antineoplastic agent Substances 0.000 claims abstract description 10
- 229940041181 antineoplastic drug Drugs 0.000 claims abstract description 10
- 238000010298 pulverizing process Methods 0.000 claims abstract description 7
- 238000010829 isocratic elution Methods 0.000 claims description 50
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 24
- 239000012043 crude product Substances 0.000 claims description 20
- 238000001556 precipitation Methods 0.000 claims description 18
- 238000004262 preparative liquid chromatography Methods 0.000 claims description 18
- 238000000338 in vitro Methods 0.000 claims description 16
- 238000012216 screening Methods 0.000 claims description 15
- 238000001514 detection method Methods 0.000 claims description 14
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 13
- 239000000945 filler Substances 0.000 claims description 12
- 239000002245 particle Substances 0.000 claims description 12
- 238000002390 rotary evaporation Methods 0.000 claims description 12
- 230000010261 cell growth Effects 0.000 claims description 11
- 201000005202 lung cancer Diseases 0.000 claims description 11
- 208000020816 lung neoplasm Diseases 0.000 claims description 11
- 239000002994 raw material Substances 0.000 claims description 10
- 238000012360 testing method Methods 0.000 claims description 10
- 239000012528 membrane Substances 0.000 claims description 9
- 239000000741 silica gel Substances 0.000 claims description 8
- 229910002027 silica gel Inorganic materials 0.000 claims description 8
- 229910021642 ultra pure water Inorganic materials 0.000 claims description 7
- 239000012498 ultrapure water Substances 0.000 claims description 7
- 238000007445 Chromatographic isolation Methods 0.000 claims description 6
- 230000008569 process Effects 0.000 claims description 5
- 238000000638 solvent extraction Methods 0.000 claims description 5
- 238000001914 filtration Methods 0.000 claims description 4
- 239000002826 coolant Substances 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 238000004090 dissolution Methods 0.000 claims description 2
- 238000000227 grinding Methods 0.000 claims description 2
- 239000006166 lysate Substances 0.000 claims 1
- 238000000605 extraction Methods 0.000 abstract description 12
- 230000000694 effects Effects 0.000 abstract description 7
- 239000002244 precipitate Substances 0.000 abstract description 2
- 238000004811 liquid chromatography Methods 0.000 abstract 4
- UREBWPXBXRYXRJ-UHFFFAOYSA-N ethyl acetate;methanol Chemical compound OC.CCOC(C)=O UREBWPXBXRYXRJ-UHFFFAOYSA-N 0.000 abstract 1
- 230000001376 precipitating effect Effects 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 36
- 210000004027 cell Anatomy 0.000 description 33
- 239000003814 drug Substances 0.000 description 21
- 239000000284 extract Substances 0.000 description 12
- 239000000463 material Substances 0.000 description 12
- 239000001963 growth medium Substances 0.000 description 10
- 241000190633 Cordyceps Species 0.000 description 8
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 8
- 206010028980 Neoplasm Diseases 0.000 description 8
- 229960004397 cyclophosphamide Drugs 0.000 description 8
- 238000005516 engineering process Methods 0.000 description 8
- 239000004615 ingredient Substances 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 8
- 239000000377 silicon dioxide Substances 0.000 description 8
- 238000003809 water extraction Methods 0.000 description 8
- 230000012010 growth Effects 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 239000013543 active substance Substances 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 238000000926 separation method Methods 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 241000233866 Fungi Species 0.000 description 4
- 239000006285 cell suspension Substances 0.000 description 4
- 238000005194 fractionation Methods 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000002699 waste material Substances 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 206010013786 Dry skin Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- VXOZCESVZIRHCJ-KGHQQZOUSA-N ergosterol peroxide Chemical compound O1O[C@@]2(C=C3)[C@@H]4CC[C@H]([C@H](C)/C=C/[C@H](C)C(C)C)[C@@]4(C)CC[C@@H]2[C@]2(C)[C@@]13C[C@@H](O)CC2 VXOZCESVZIRHCJ-KGHQQZOUSA-N 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 238000000247 postprecipitation Methods 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- BOSXJGUQRALKDK-UHFFFAOYSA-N 2,6-dimethyldecan-3-ol Chemical compound CCCCC(C)CCC(O)C(C)C BOSXJGUQRALKDK-UHFFFAOYSA-N 0.000 description 1
- 241000707825 Argyrosomus regius Species 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- KQLDDLUWUFBQHP-UHFFFAOYSA-N Cordycepin Natural products C1=NC=2C(N)=NC=NC=2N1C1OCC(CO)C1O KQLDDLUWUFBQHP-UHFFFAOYSA-N 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 241000130660 Hepialidae Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 238000003811 acetone extraction Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- VBIXEXWLHSRNKB-UHFFFAOYSA-N ammonium oxalate Chemical compound [NH4+].[NH4+].[O-]C(=O)C([O-])=O VBIXEXWLHSRNKB-UHFFFAOYSA-N 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- SCJNCDSAIRBRIA-DOFZRALJSA-N arachidonyl-2'-chloroethylamide Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)NCCCl SCJNCDSAIRBRIA-DOFZRALJSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- OFEZSBMBBKLLBJ-BAJZRUMYSA-N cordycepin Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)C[C@H]1O OFEZSBMBBKLLBJ-BAJZRUMYSA-N 0.000 description 1
- OFEZSBMBBKLLBJ-UHFFFAOYSA-N cordycepine Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(CO)CC1O OFEZSBMBBKLLBJ-UHFFFAOYSA-N 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000002380 cytological effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000002481 ethanol extraction Methods 0.000 description 1
- 238000003810 ethyl acetate extraction Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 210000004332 phalangeal cell Anatomy 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention provides a method for extracting an anti-tumor active component from Cordyceps militaris, which includes the steps: ultrafine-pulverizing a Cordyceps militaris fruiting body to obtain ultrafine powder, decocting with water for extraction, precipitating, then extracting with acetone, dissolving the precipitate, separating with liquid chromatography, and eluting with 100% n-hexane, 25% ethyl acetate-n-hexane and 100% ethyl acetate as eluants; collecting the component with the highest activity, separating with liquid chromatography, and eluting with 100% n-hexane, 10% ethyl acetate-n-hexane, 15% ethyl acetate-n-hexane, 30% ethyl acetate-n-hexane, 60% ethyl acetate-n-hexane and 100% methanol as eluants; collecting the component with the highest activity, separating with liquid chromatography, performing gradient elution with ethyl acetate-methanol; collecting the component with the highest activity, separating with liquid chromatography, and eluting with 100% n-hexane, 20% dichloromethane-n-hexane and 25% dichloromethane-n-hexane as eluants; and collecting the component (target component) with the highest activity. The method provided by the invention has good repeatability, and the obtained active component can be used for preparing anti-tumor drugs.
Description
Technical field
The present invention relates to biological product processing technique field, be specifically related to a kind of method of extracting antitumor component from Cordyceps militaris (L.) Link., and this active component is in the application of preparing in antitumor drug.
Background technology
Tumor is a kind of genopathy, but is not hereditary, it be phalangeal cell under carcinogenic factor effect, having there is change in gene, loses the normal regulation to its growth, causes monoclonicity paraplasm and the neoplasm that forms.2008, the data show that WHO issues, China has become second-biggest-in-the-world cancer state occurred frequently, and annual newly-increased 2,200,000 cancer patients of China, account for 20% of global cancer patient sum, and especially hepatocarcinoma, gastric cancer and pulmonary carcinoma become main Health Killer.How research is eliminated cancer, is allowed cancer patient can live ground better, it is the research emphasis in field of medicaments, therefore find efficient, low toxicity, the desirable new type antineoplastic medicine that has clinical value that selectivity is strong and be a long-term and difficult task, the important directions that seeking antitumor medicine has become antitumor drug exploitation from the nontoxic of medicine-food two-purpose and Chinese medicine that raw material is cheap and easy to get with wish place.
Cordyceps is that Cordyceps colonizes in the entomogenous fungi complex take it as carrier in Lepidoptera Hepialidae larva, contain rich in protein, fat, cordycepic acid, nucleosides material and several amino acids isoreactivity material, taste delicate fragrance, has lung nourishing and qi invigorating, increases smart the kidney invigorating, hemostasis and phlegm, inhibition tumor, cough-relieving calmness, wind dispelling, heat radiation, stays effect of Rong Meiyan, slow down aging, raising immunity of organisms.
Cordyceps militaris (L.) Link. (Cordycepsmilitaris) is attributed to Cordyceps with Cordyceps is same on taxonomy, is a kind of medicinal fungi of preciousness, and its chemical composition is similar to Cordyceps with pharmacological action, often substitutes clinically Cordyceps and is used as medicine.Because wild cordyceps militaris resource is very limited, can not meet the market demand day by day increasing, Artificial Cultivation of Cordyceps militaris Link becomes essential.At present, Artificial Cultivation of Cordyceps militaris Link is succeeded, and has realized large-scale production.
Cordyceps militaris (L.) Link. has the multiple active substance relevant to antitumor action, and some active substance has been studied more deeply as the antitumor action of cordycepin, Cordyceps polysaccharide etc.; Some active substance is as less in the research of anti-tumor aspect in carotenoid, protein etc.Cordyceps militaris (L.) Link. active substance fails farthest to be develop and useedd, so research has the new active substance of antitumor action, constantly new physiologically active and the pharmacological action of the existing active substance of developing are significant, can provide fundamental basis and industrialization background in the application aspect medical for further researching and developing Cordyceps militaris (L.) Link..
The extracting method of traditional Cordyceps militaris (L.) Link. antitumor component, in " in-vitro screening of Cordyceps militaris (L.) Link. antitumor and Immunoactive site " (the edible fungi journal .2011.18 (1): 41-45) delivering as Du Xiuju etc., a kind of militaris sporocarp extract preparation method is disclosed: Cordyceps militaris (L.) Link.sporophore powder is crossed after 60 mesh sieves, with chloroform extraction 2 hours, filter, filtering residue is air-dry rear with ethyl acetate extraction 2 hours, filter, air-dry rear use 95% ethanol extraction of filtering residue 2 hours, filter, 30 times of 100 ℃ of distilled water extraction of the air-dry rear use of filtering residue 2 hours, the centrifugal 20min postprecipitation of 400g extracts 2 hours with 15 times 100 ℃ 3% ammonium oxalate solutions, the centrifugal 20min postprecipitation of 400g extracts 2 hours with 10 times of 100 ℃ of 5%NaOH solution, after the centrifugal 20min of 400g, supernatant continues with 4 ℃ of neutralizations of 1mol/L hydrochloric acid, the centrifugal 20min of 400g, the filtrate that each step is obtained or supernatant vacuum concentration, lyophilization, obtain each extract components.The extraction separation method step of this Cordyceps militaris (L.) Link.sporophore effective ingredient is numerous and diverse, and the active component extracting is few.In addition, adopt this traditional solvent extraction to carry out the extraction of effective active component, between batch, do not there is repeatability, cannot guarantee that material composition and second batch that first extraction obtains extract the concordance between the material composition obtaining.
A kind of isolation and purification method of target compound is disclosed in separation and purification and the antitumor action of-adenosine " the N6-(2-ethoxy in Cordyceps militaris (L.) Link.sporophore) " (edible fungi journal .2013.20 (1): 62-65) that and for example Zhu Lina etc. delivers, it adds in distilled water 100 ℃ to extract 2 hours in Cordyceps militaris (L.) Link.sporophore powder, repeat to extract 2 times, merge extractive liquid,, then carries out the extraction of succeeding target composition with this extracting solution.The method belongs to the extracting method of traditional Effective Component of Chinese Medicine, carry out the extraction of effective ingredient with the supernatant of water extraction, and the precipitation of water extraction is not carried out to deep research, this likely causes the loss of a large amount of active components, thereby has hindered the progress of Cordyceps militaris (L.) Link. aspect antitumor drug exploitation.
Summary of the invention
Technical problem to be solved by this invention is for above the deficiencies in the prior art, break through the restriction that existing Chinese medicine active component extracts, a kind of method of extracting antitumor component from Cordyceps militaris (L.) Link. is provided, the method is precipitated as raw material with the Cordyceps militaris (L.) Link.sporophore water extraction that there is no anti-tumor activity on cellular level, after acetone extraction, isolates strong active antitumor component again by the active guiding of preparative liquid chromatography technology.
The technical solution adopted in the present invention is:
A method of extracting antitumor component from Cordyceps militaris (L.) Link., the method comprises the following steps:
1, pulverizing at ultralow temperature:
The Cordyceps militaris (L.) Link.sporophore of getting oven dry is raw material, puts into super micron mill and carries out micronizing, pulverizes the overall process water of 2～10 ℃ as micronized pulverization machine internal coolant simultaneously, and the micronizing time is 5-20min, obtains superfine powder.
Above-mentioned grinding time is preferably 12min.
2, solvent extraction:
2.1 decocting in water: add ultra-pure water in superfine powder, the addition of ultra-pure water is 8～10 times of superfine powder quality, 100 ℃ of heating are extracted for 3～10 hours, and centrifuging and taking precipitation, then repeats 1～3 time, and the precipitation obtaining is merged, dry, obtains crude product A.
This step is different from the maximum of at present traditional Chinese medicine active component or extracts active ingredients.In traditional Chinese medicine, the extracting method of active component or active component is all to carry out the extraction of effective ingredient take the supernatant of water extraction as intermediate raw material, in Chinese medicine, to drink be also like this to Chinese medicine, after decocting in water, getting supernatant is patients, because understand routinely, effective ingredient after boiling water decocts in medical material is just dissolved in liquid, therefore comprised required active component in supernatant.And the limitation of this understanding has exactly limited the exploitation of active component in current species or active component, make a lot of active components or effective ingredient be outwelled, further not be found and develop as waste residue.This is not also because most researchers has been ignored the probability that active component in waste residue or effective ingredient exist, but because waste residue may not have anti-tumor activity in vitro or activity is very weak, the crude product A obtaining as this step does not have anti-tumor activity after testing on cellular level, such testing result makes most researchers abandon it to be further analyzed and to study, thereby has caused the loss of a large amount of active components.The present invention is by applicant's further investigation, analysis and experiment, find not have the water extraction precipitation of anti-tumor activity to there is the probability of object active component on cellular level, thereby precipitate, from water extraction, by a large amount of experimental exploring and process optimization, finally summing up a set of is the extracting method of Cordyceps militaris (L.) Link. antitumor component of the present invention, finally successfully extracts object effective active component.
2.2 acetone precipitations: add acetone in crude product A, the addition of acetone is 2～4 times of crude product A quality, lixiviate 12～36 hours under room temperature, gets precipitation after centrifugal, then repeats 1～3 time, and the precipitation obtaining is merged, dry, obtains crude product B.
Above-mentioned centrifugal rotating speed is preferably 6000rpm.
Above-mentioned dry being preferably in 60 ℃ of air dry ovens carried out.
3, chromatographic isolation:
3.1 get crude product for B 50% ethyl acetate-hexane solution (being that ethyl acetate and normal hexane form take the volume ratio proportioning of 1:1) be dissolved to concentration as 50mg/ml, cross the organic microporous filter membrane of 0.45 μ m, then separate by preparative liquid chromatography, type of elution is 100% normal hexane isocratic elution, 25% ethyl acetate-hexane solution (being that ethyl acetate and normal hexane form with the volume ratio proportioning of 1:3) isocratic elution, 100% ethyl acetate isocratic elution, detection wavelength is 260nm, obtain each component after anti tumor activity in vitro screening, choose the strongest active component concentrated by rotary evaporation final vacuum dry, obtain component A.
Particularly, silica gel (Silica), size that the chromatographic column filler using is particle diameter 10 μ m are 150 × 250mm, type of elution is 100% normal hexane isocratic elution 10min, 25% ethyl acetate-hexane solution isocratic elution 25min, 100% ethyl acetate isocratic elution 15min, applied sample amount is 200ml, and flow velocity is 700ml/min.
The selection of this step solvent is extremely important, through overtesting, in 50% ethyl acetate-hexane solution, ethyl acetate can all be dissolved crude product B, normal hexane to crude product B for being partly dissolved, and select 50% ethyl acetate-hexane solution can accomplish to make crude product B to be dissolved to 50mg/ml, and when eluting, adopt the eluting order of 100% normal hexane, 25% ethyl acetate-hexane solution, 100% ethyl acetate, material composition in crude product B is separated as far as possible, be conducive to the extraction of object active component, improve extraction ratio.
3.2 to get component A 100% acetic acid ethyl dissolution to concentration be 50mg/ml, cross the organic microporous filter membrane of 0.45 μ m, then separate by preparative liquid chromatography, type of elution is 100% normal hexane isocratic elution 10min, 10% ethyl acetate-hexane solution eluting 50min, 15% ethyl acetate-hexane solution eluting 20min, 30% ethyl acetate-hexane solution eluting 15min, 60% ethyl acetate-hexane solution eluting 20min, 100% methanol isocratic elution 10min, type of elution is 100% normal hexane isocratic elution, 10% ethyl acetate-hexane solution isocratic elution, 15% ethyl acetate-hexane solution isocratic elution, 30% ethyl acetate-hexane solution isocratic elution, 60% ethyl acetate-hexane solution isocratic elution, 100% methanol isocratic elution, detection wavelength is 260nm, obtain each component after anti tumor activity in vitro screening, choose the strongest active component concentrated by rotary evaporation final vacuum dry, obtain B component.
Particularly, silica gel (Silica), size that the chromatographic column filler using is particle diameter 10 μ m are 150 × 250mm, type of elution is 100% normal hexane isocratic elution 10min, 10% ethyl acetate-hexane solution eluting 50min, 15% ethyl acetate-hexane solution eluting 20min, 30% ethyl acetate-hexane solution eluting 15min, 60% ethyl acetate-hexane solution eluting 20min, 100% methanol isocratic elution 10min, applied sample amount is 400ml, flow velocity is 700ml/min.
The eluant (100% normal hexane, 10% ethyl acetate-normal hexane, 15% ethyl acetate-normal hexane, 30% ethyl acetate-normal hexane, 60% ethyl acetate-normal hexane, 100% methanol) that this step eluting adopts is different from 3.1, by the difference of eluting rate, the component originally being eluted by a concentration is separated to eluting, be conducive to the acquisition of follow-up active component.
3.3 to get B component 100% dissolve with methanol to concentration be 50mg/ml, cross the organic microporous filter membrane of 0.45 μ m, then separate by preparative liquid chromatography, type of elution is 100% ethyl acetate～100% methanol gradient elution, detection wavelength is 260nm, obtain each component after anti tumor activity in vitro screening, choose the strongest active component concentrated by rotary evaporation final vacuum dry, obtain component C.
Particularly, silica gel (Silica), size that the chromatographic column filler of use is particle diameter 10 μ m are 150 × 250mm, and type of elution is 100% ethyl acetate～100% methanol gradient elution 30min, and applied sample amount is 400ml, and flow velocity is 700ml/min.
3.4 get component for C 20% dichloromethane-hexane solution to be dissolved to concentration be 50mg/ml, cross the organic microporous filter membrane of 0.45 μ m, then separate by preparative liquid chromatography, type of elution is 100% normal hexane isocratic elution, 20% dichloromethane-hexane solution isocratic elution, 25% dichloromethane-hexane solution isocratic elution, detection wavelength is 260nm, obtain each component after anti tumor activity in vitro screening, choose the strongest active component, concentrated by rotary evaporation final vacuum is dry, is the object of the invention antitumor component.
Particularly, silica gel (Silica), size that the chromatographic column filler using is particle diameter 10 μ m are 21.2 × 250mm, type of elution is 100% normal hexane isocratic elution 8min, 20% dichloromethane-hexane solution isocratic elution 37min, 25% dichloromethane-hexane solution isocratic elution 15min, applied sample amount is 2ml, and flow velocity is 15ml/min.
The key of said extracted method is chromatographic isolation, and the key of chromatographic isolation is mobile phase, by selection, the repeatedly selection of different mobile phase kinds and different proportionings between chromatographic isolation of different proportion of mobile phase in the selection of mobile phase kind, a same to chromatographic separation process, component in Cordyceps militaris (L.) Link. is fully separated, thereby make successfully from Cordyceps militaris (L.) Link., to extract object antitumor component, make to extract the antitumor component purity obtaining high.
In described step (3), anti tumor activity in vitro screening refers to and suppresses people's lung cancer A549 cell growth test and suppress the test of people's hepatocarcinoma Hep-G2 Growth of Cells, particularly, refer to the growing state that adopts real-time unmarked dynamic cellular analytical technology to detect in real time dosing descendant lung cancer A549 cell and people's hepatocarcinoma Hep-G2 cell, can obtain the cytological effect curve of medicine mediation simultaneously, judge the whether growth of anticancer of this medicine by this curve.Be with traditional method (MTT) comparative benefits, experimental implementation is simple, and step is few, and personal error is little.Adopt unmarked method, do not have labeling effciency problem, and to cell not damaged, cell detects approaching most under physiological status, and result precision is high.Experimental result is objective, reproducible, does not need to arrange repeating hole.The method can judge the anti-tumor activity of component to be measured well, because in experimenting, we find out that, each component to be measured is synchronous to the inhibition of these two kinds of cells substantially, do not exist No. 1 component to people's lung cancer A549 cell inhibitory action preferably and the 2nd component to the best situation of people's hepatocarcinoma Hep-G2 cyto-inhibition, substantially the object component of choosing or be all best to the inhibitory action of two kinds of cells, otherwise all poor to all component inhibitions of the best and another kind of cell of a kind of cyto-inhibition wherein.
The present invention also further provides the above-mentioned antitumor component obtaining of extracting from Cordyceps militaris (L.) Link. in the application of preparing in antitumor drug.This active component is made all kinds of pharmaceutical formulations with pharmaceutically acceptable any carrier according to a conventional method as effective ingredient.
Compared with prior art, the present invention has following remarkable advantage and beneficial effect:
1, the present invention adopts super micron mill to carry out superfine comminution at low temperature, to abolish the hard cell wall of Cordyceps militaris (L.) Link.sporophore, is conducive to the stripping of content, has effectively improved the extraction ratio of antitumor component in Cordyceps militaris (L.) Link.sporophore;
2, the present invention adopts preparative liquid chromatography to carry out the separation and purification of material composition, the technology of uses advanced is to being not have the water extraction precipitation of anti-tumor activity to carry out separation and purification on cellular level, select by the reagent to each separating step, the optimization of process conditions and technological parameter, and good synergism between each separating step, finally successfully extract antitumor component, with respect to traditional solvent extraction, not only good stability of the extracting method of this antitumor component, reproducible, between the material composition obtaining batch, concordance is high, and extraction ratio is high, the active component obtaining has powerful antitumor activity,
3, the present invention judges the extracorporeal anti-tumor ability of Cordyceps militaris (L.) Link. antitumor component by people's lung cancer A549 cell growth inhibition test and people's hepatocarcinoma Hep-G2 cell growth inhibition test, and establishes positive control, visual result, easily judgement;
4, the extracting method technique of Cordyceps militaris (L.) Link. antitumor component of the present invention is simple, easy to implement, have quick, efficient, reproducible, stablize controlled, separation and purification preparation amount large, be applicable to the features such as large-scale industrialization production, the Cordyceps militaris (L.) Link. antitumor component of gained can be used for research and development and prepares antitumor drug, and because this active component antitumor active constituent content is high, while using this active component to be prepared antitumor drug, active constituent content is high, can meet the demand of different preparations carrier forms to active constituent content;
5, the present invention has expanded the raw material sources of antitumor drug or health food, has expanded the range of application of Cordyceps militaris (L.) Link.sporophore, makes Cordyceps militaris (L.) Link.sporophore become the active component raw material of antitumor drug, has significantly improved the added value of Cordyceps militaris (L.) Link.sporophore.
Accompanying drawing explanation
Shown in Fig. 1 is embodiment of the present invention 1(3) chromatographic fractionation figure that (a) step obtains;
Shown in Fig. 2 is embodiment of the present invention 1(3) chromatographic fractionation figure that (b) step obtains;
Shown in Fig. 3 is embodiment of the present invention 1(3) chromatographic fractionation figure that (c) step obtains;
Shown in Fig. 4 is embodiment of the present invention 1(3) chromatographic fractionation figure that (d) step obtains;
Shown in Fig. 5 is that Cordyceps militaris (L.) Link. antitumor component prepared by the embodiment of the present invention 1 suppresses the cell detection figure in real time that people's lung cancer A549 cell is grown, and wherein C310-12-1-17 is object component (intermediate curve), and hlxa is cyclophosphamide (lower surface curve);
Shown in Fig. 6 is the cell detection figure in real time that the Cordyceps militaris (L.) Link. antitumor component prepared of the embodiment of the present invention 1 suppresses people's hepatocarcinoma Hep-G2 Growth of Cells, and wherein C310-12-1-17 is object component (intermediate curve), and hlxa is cyclophosphamide (lower surface curve);
Shown in Fig. 7 is the molecular structural formula of peroxy-ergosterol.
The specific embodiment
Below in conjunction with embodiment, the present invention is further described in detail.Be noted that following illustrating is all exemplary, be intended to the invention provides further instruction.Except as otherwise noted, all Science and Technology terms that the present invention uses have the identical meanings of conventionally understanding with the technical field of the invention personnel.
Embodiment 1: extract antitumor component from Cordyceps militaris (L.) Link.
1, raw material, material:
Cordyceps militaris (L.) Link.sporophore is this Laboratory Production.
2, reagent:
Ultra-pure water is produced by Mi Libo pure water instrument; Acetone is purchased from the north, Tianjin day medical chemistry chemical reagent work; Chromatographic grade ethyl acetate, normal hexane, dichloromethane, methanol are purchased from Honeywell company.
3, instrument and equipment:
Super micron mill is purchased from Sanqing Stainless Steel Apparatus Co., Ltd., Shandong; Tabletop refrigerated centrifuge is purchased from Thermo company; Rotary Evaporators is purchased from Shanghai Ya Rong biochemical instrument factory; Chromatographic column (10 μ msilica150 × 250mm) is purchased from Jiangsu Di Wote instrument and equipment Science and Technology Ltd.; Chromatographic column (10 μ msilica21.2 × 250mm) is purchased from Tianjin Bonaaijieer Technology Co.,Ltd.
The step of extracting antitumor component from Cordyceps militaris (L.) Link.sporophore is as follows:
(1) pulverizing at ultralow temperature:
The Cordyceps militaris (L.) Link.sporophore of getting oven dry is raw material, take the Cordyceps militaris (L.) Link.sporophore that 150g is dried, put into super micron mill and carry out micronizing, pulverize the overall process water of 2～10 ℃ as micronized pulverization machine internal coolant simultaneously, pulverize temperature to reduce, guarantee release and bioactive the stablizing of effective ingredient, the micronizing time is 5-20min, grope 12min for the most suitable through practice, obtain superfine powder.
(2) solvent extraction:
(a) decocting in water: add ultra-pure water in superfine powder, the addition of ultra-pure water is 8～10 times of superfine powder quality, 100 ℃ of heating are extracted for 3～10 hours, 6000rpm centrifuging and taking precipitation, then repeat twice, the precipitation obtaining for three times is merged, at 60 ℃ of air dry oven inner dryings, obtain crude product A.
(b) acetone precipitation: add acetone in crude product A, the addition of acetone is 3 times of crude product A quality, lixiviate 12～36 hours under room temperature, after 6000rpm is centrifugal, get precipitation, then repeat twice, the precipitation obtaining for three times is merged, at 60 ℃ of air dry oven inner dryings, obtain crude product B.
(3) chromatographic isolation:
(a) get crude product for B 50% ethyl acetate-hexane solution to be dissolved to concentration be 50mg/ml, cross the organic microporous filter membrane of 0.45 μ m, then separate by preparative liquid chromatography.Chromatographic column filler is that silica, the size of particle diameter 10 μ m is 150 × 250mm, type of elution is 100% normal hexane isocratic elution 10min, 25% ethyl acetate-hexane solution isocratic elution 25min, 100% ethyl acetate isocratic elution 15min, applied sample amount is 200ml, flow velocity is 700ml/min, detection wavelength is 260nm, and chromatogram as shown in Figure 1, obtains each component after anti tumor activity in vitro screening, choose the strongest active component concentrated by rotary evaporation final vacuum dry, obtain component C3-10.
(b) get component C3-10 100% ethyl acetate 50 and spend ultrasonicly to be just dissolved to concentration be 50mg/ml, cross the organic microporous filter membrane of 0.45 μ m, then separate by preparative liquid chromatography.Chromatographic column filler is the silica of particle diameter 10 μ m, size is 150 × 250mm, type of elution is 100% normal hexane isocratic elution 10min, 10% ethyl acetate-hexane solution eluting 50min, 15% ethyl acetate-hexane solution eluting 20min, 30% ethyl acetate-hexane solution eluting 15min, 60% ethyl acetate-hexane solution eluting 20min, 100% methanol isocratic elution 10min, applied sample amount is 400ml, flow velocity is 700ml/min, detection wavelength is 260nm, chromatogram as shown in Figure 2, obtain each component after anti tumor activity in vitro screening, choose the strongest active component concentrated by rotary evaporation final vacuum dry, obtain component C310-12.
(c) get component C310-12 100% methanol 50 and spend ultrasonicly to be just dissolved to concentration be 50mg/ml, cross the organic microporous filter membrane of 0.45 μ m, then separate by preparative liquid chromatography.Chromatographic column filler is that silica, the size of particle diameter 10 μ m is 150 × 250mm, type of elution is 100% ethyl acetate～100% methanol gradient elution 30min, applied sample amount is 400ml, flow velocity is 700ml/min, detection wavelength is 260nm, and chromatogram as shown in Figure 3, obtains each component after anti tumor activity in vitro screening, choose the strongest active component concentrated by rotary evaporation final vacuum dry, obtain component C310-12-1.
(d) get component for C310-12-1 20% dichloromethane-hexane solution 50 spend ultrasonicly to be just dissolved to concentration be 50mg/ml, cross the organic microporous filter membrane of 0.45 μ m, then separate by preparative liquid chromatography.Chromatographic column filler is the silica of particle diameter 10 μ m, size is 21.2 × 250mm, type of elution is 100% normal hexane isocratic elution 8min, 20% dichloromethane-hexane solution isocratic elution 37min, 25% dichloromethane-hexane solution isocratic elution 15min, applied sample amount is 2ml, flow velocity is 15ml/min, detection wavelength is 260nm, chromatogram as shown in Figure 4, obtain each component after anti tumor activity in vitro screening, choose the strongest active component, concentrated by rotary evaporation final vacuum is dry, obtain component C310-12-1-17, 0.3g altogether, be the object of the invention antitumor component.
Antitumor component C310-12-1-17 obtained above is through the further separation and purification of preparative hplc and NMR carbon spectrum hydrogen analysis of spectrum, and preliminary judgement mainly contains peroxy-ergosterol (molecular structural formula as shown in Figure 7) and other unknown materials.
Embodiment 2: suppress people's lung cancer A549 cell growth test
Main material and reagent:
People's lung cancer A549 cell is given by Acea Bio. (Hangzhou) Co., Ltd.; F-12K culture medium is given by Gibco company; Cyclophosphamide is purchased from Tianjin Jinshi Pharmaceutical Co., Ltd..
Blank hole: do not add medicine;
Positive control hole: add cyclophosphamide;
Experimental port: the antitumor component C310-12-1-17 that adds embodiment 1 gained.
Cell culture:
At 5%CO
2, 37 ℃, under saturated humidity, with F-12K(10%FBS+1%PS) culture medium culturing people lung cancer A549 cell, choose the cell of logarithmic (log) phase growth as experimental cell.After cell counting, be the about cell suspension of 5.7 ten thousand/mL with culture medium dilution.
Growth of Cells condition monitoring:
Cell real-time monitor is put into 5%CO
2, in 37 ℃ of saturated humidity incubators.Get 8 orifice plates, every hole adds 150 μ LF-12K culture medium, puts into cell real-time monitor and walks baseline, after covering baseline, take out octal plate, every hole adds the A549 cell suspension 345 μ L that diluted, to every porocyte number approximately 20,000, leave standstill 3min, under inverted microscope, whether observation of cell is even.It is required drug level (25 μ g/ml) that every hole adds medicine (C310-12-1-17) to the final concentration that 5 μ L have diluted, with the cyclophosphamide of same concentrations as positive controls, contain the culture medium of 0.1%DMSO as blank group, put into cell real-time monitor and detect, detect Taking Pictures recording when complete.As shown in Figure 5, result shows experimental result: the present invention extracts the Cordyceps militaris (L.) Link. antitumor component C310-12-1-17 obtaining and can reach in the time of 25 μ g/ml 100% inhibition human lung cancer cell A549's growth.
Embodiment 3: suppress the test of people's hepatocarcinoma Hep-G2 Growth of Cells
Main material and reagent:
People's hepatocarcinoma Hep-G2 cell is given by huge Technology Park; MEM culture medium is given by Gibco company; Cyclophosphamide is purchased from Tianjin Jinshi Pharmaceutical Co., Ltd..
Blank hole: do not add medicine;
Positive control hole: add cyclophosphamide;
Experimental port: the antitumor component C310-12-1-17 that adds embodiment 1 gained.
Cell culture:
At 5%CO
2, 37 ℃, under saturated humidity, with MEM(10%FBS, 1%PS) and culture medium people's pulmonary carcinoma Hep-G2 cell, choose cell that growth conditions is good as experimental cell.After cell counting, be the about cell suspension of 5.7 ten thousand/mL with culture medium dilution.
Growth of Cells condition monitoring:
Cell real-time monitor is put into 5%CO
2, in 37 ℃ of saturated humidity incubators.Get 8 orifice plates, every hole adds 150 μ LMEM culture medium, puts into cell real-time monitor and walks baseline, after covering baseline, take out octal plate, every hole adds the Hep-G2 cell suspension 345 μ L that diluted, to every porocyte number approximately 40,000, leave standstill 3min, under inverted microscope, whether observation of cell is even.It is required drug level (25 μ g/ml) that every hole adds medicine (C310-12-1-17) to the final concentration that 5 μ L have diluted, with the cyclophosphamide of same concentrations as positive controls, contain the culture medium of 0.1%DMSO as blank group, put into cell real-time monitor and detect, detect Taking Pictures recording when complete.As shown in Figure 6, result shows experimental result: the present invention extracts the Cordyceps militaris (L.) Link. antitumor component C310-12-1-17 obtaining can reach 100% inhibition human liver cancer cell Hep-G2 growth in the time of 25 μ g/ml.
Because Cordyceps militaris (L.) Link. itself is with regard to edible, so it has the features such as nontoxic, safe, can obtain effective antitumour new drug and/or anti-tumor health care product by Cordyceps militaris (L.) Link. antitumor component of the present invention, there is feature efficient, nontoxic and that the relative Cordyceps of raw material is cheap and easy to get.Because C310-12-1-17 mainly contains 2,6-dimethyl 3-hydroxyl decane, in the time that concentration is 25 μ g/ml, can reach the growth of 100% inhibition human lung cancer cell A549 and human liver cancer cell Hep-G2, this has shown the potentiality of C310-12-1-17 aspect further exploitation effective antitumour monomer medicine.Next we will carry out active component C310-12-1-17 to prepare on a large scale, strive for obtaining the strong activated monomer compound of antitumor, develop strong active antitumor monomer medicine, for the mankind's health is offered as a tribute our meagre strength.
Material, reagent and experimental facilities that the embodiment of the present invention relates to, if no special instructions, be the common commercially available prod that meets biological product processing.
The above, be only the preferred embodiments of the present invention, should be understood that; for those skilled in the art; not departing under the prerequisite of core technology of the present invention, can also make improvements and modifications, these improvements and modifications also should belong to scope of patent protection of the present invention.Any change in implication and the scope suitable with claims of the present invention, all should think to be included in the scope of claims.
Claims (8)
1. a method of extracting antitumor component from Cordyceps militaris (L.) Link., is characterized in that comprising the following steps:
(1) pulverizing at ultralow temperature:
The Cordyceps militaris (L.) Link.sporophore of getting oven dry is raw material, puts into super micron mill and carries out micronizing, pulverizes the overall process water of 2～10 ℃ as micronized pulverization machine internal coolant simultaneously, and the micronizing time is 5-20min, obtains superfine powder;
(2) solvent extraction:
Decocting in water: add ultra-pure water in superfine powder, the addition of ultra-pure water is 8～10 times of superfine powder quality, 100 ℃ of heating are extracted for 3～10 hours, and centrifuging and taking precipitation, then repeats 1～3 time, and the precipitation obtaining is merged, dry, obtains crude product A;
Acetone precipitation: add acetone in crude product A, the addition of acetone is 2～4 times of crude product A quality, lixiviate 12～36 hours under room temperature, gets precipitation after centrifugal, then repeats 1～3 time, and the precipitation obtaining is merged, dry, obtains crude product B;
(3) chromatographic isolation:
(a) get crude product for B 50% ethyl acetate-hexane solution to be dissolved to concentration be 50mg/ml, then separate by preparative liquid chromatography, type of elution is 100% normal hexane isocratic elution, 25% ethyl acetate-hexane solution isocratic elution, 100% ethyl acetate isocratic elution, detection wavelength is 260nm, obtains each component after anti tumor activity in vitro screening, choose the strongest active component concentrated by rotary evaporation final vacuum dry, obtain component A;
(b) getting component A 100% acetic acid ethyl dissolution to concentration is 50mg/ml, then separate by preparative liquid chromatography, type of elution is 100% normal hexane isocratic elution, 10% ethyl acetate-hexane solution isocratic elution, 15% ethyl acetate-hexane solution isocratic elution, 30% ethyl acetate-hexane solution isocratic elution, 60% ethyl acetate-hexane solution isocratic elution, 100% methanol isocratic elution, detection wavelength is 260nm, obtain each component after anti tumor activity in vitro screening, choose the strongest active component concentrated by rotary evaporation final vacuum dry, obtain B component,
(c) getting B component 100% dissolve with methanol to concentration is 50mg/ml, then separate by preparative liquid chromatography, type of elution is 100% ethyl acetate～100% methanol gradient elution, detection wavelength is 260nm, obtain each component after anti tumor activity in vitro screening, choose the strongest active component concentrated by rotary evaporation final vacuum dry, obtain component C;
(d) get component for C 20% dichloromethane-hexane solution to be dissolved to concentration be 50mg/ml, then separate by preparative liquid chromatography, type of elution is 100% normal hexane isocratic elution, 20% dichloromethane-hexane solution isocratic elution, 25% dichloromethane-hexane solution isocratic elution, detection wavelength is 260nm, obtain each component after anti tumor activity in vitro screening, choose the strongest active component, concentrated by rotary evaporation final vacuum is dry, is the object of the invention antitumor component.
2. a kind of method of extracting antitumor component from Cordyceps militaris (L.) Link. according to claim 1, is characterized in that: in described step (1), grinding time is 12min.
3. a kind of method of extracting antitumor component from Cordyceps militaris (L.) Link. according to claim 1, is characterized in that: in described step (2), centrifugal rotating speed is 6000rpm.
4. a kind of method of extracting antitumor component from Cordyceps militaris (L.) Link. according to claim 1, is characterized in that: in described step (2), be dried in 60 ℃ of air dry ovens and carry out.
5. a kind of method of extracting antitumor component from Cordyceps militaris (L.) Link. according to claim 1, is characterized in that:
Described step (3) (a) in the chromatographic column filler that uses of preparative liquid chromatography be particle diameter 10 μ m silica gel, size are 150 × 250mm, type of elution is 100% normal hexane isocratic elution 10min, 25% ethyl acetate-hexane solution isocratic elution 25min, 100% ethyl acetate isocratic elution 15min, applied sample amount is 200ml, and flow velocity is 700ml/min;
Described step (3) (b) in the chromatographic column filler that uses of preparative liquid chromatography be particle diameter 10 μ m silica gel, size are 150 × 250mm, type of elution is 100% normal hexane isocratic elution 10min, 10% ethyl acetate-hexane solution eluting 50min, 15% ethyl acetate-hexane solution eluting 20min, 30% ethyl acetate-hexane solution eluting 15min, 60% ethyl acetate-hexane solution eluting 20min, 100% methanol isocratic elution 10min, applied sample amount is 400ml, and flow velocity is 700ml/min;
Described step (3) (c) in the chromatographic column filler that uses of preparative liquid chromatography be particle diameter 10 μ m silica gel, size are 150 × 250mm, type of elution is 100% ethyl acetate～100% methanol gradient elution 30min, applied sample amount is 400ml, and flow velocity is 700ml/min;
Described step (3) (d) in the chromatographic column filler that uses of preparative liquid chromatography be particle diameter 10 μ m silica gel, size are 21.2 × 250mm, type of elution is 100% normal hexane isocratic elution 8min, 20% dichloromethane-hexane solution isocratic elution 37min, 25% dichloromethane-hexane solution isocratic elution 15min, applied sample amount is 2ml, and flow velocity is 15ml/min.
6. a kind of method of extracting antitumor component from Cordyceps militaris (L.) Link. according to claim 1, is characterized in that: in described step (3), lysate was first used 0.45 μ m organic membrane sucking filtration before being prepared liquid chromatograph.
7. a kind of method of extracting antitumor component from Cordyceps militaris (L.) Link. according to claim 1, is characterized in that: in described step (3), anti tumor activity in vitro screening refers to and suppresses people's lung cancer A549 cell growth test and suppress the test of people's hepatocarcinoma Hep-G2 Growth of Cells.
8. the antitumor component obtaining of extracting from Cordyceps militaris (L.) Link. claimed in claim 1 is in the application of preparing in antitumor drug.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410040147.3A CN103784481B (en) | 2014-01-27 | 2014-01-27 | A kind of method and application thereof extracting antitumor component from Cordyceps militaris (L.) Link. |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410040147.3A CN103784481B (en) | 2014-01-27 | 2014-01-27 | A kind of method and application thereof extracting antitumor component from Cordyceps militaris (L.) Link. |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103784481A true CN103784481A (en) | 2014-05-14 |
| CN103784481B CN103784481B (en) | 2016-06-01 |
Family
ID=50660818
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410040147.3A Expired - Fee Related CN103784481B (en) | 2014-01-27 | 2014-01-27 | A kind of method and application thereof extracting antitumor component from Cordyceps militaris (L.) Link. |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103784481B (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105055428A (en) * | 2015-09-14 | 2015-11-18 | 广州普立森生物科技有限公司 | Application of peroxy-ergosterol in preparation of medicament for treating primary liver cancer |
| CN105380994A (en) * | 2015-12-09 | 2016-03-09 | 正源堂（天津）生物科技有限公司 | Extraction method and application of Nux Vomica antitumor active components |
| CN111329871A (en) * | 2020-03-13 | 2020-06-26 | 贵州贵安精准医学研究院股份有限公司 | Preparation method and application of product of cordyceps militaris for preventing and treating liver cancer |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1115671A (en) * | 1994-07-25 | 1996-01-31 | 林清渊 | Active component of cordyceps sinensis and its separation method |
| CN101007025A (en) * | 2006-01-24 | 2007-08-01 | 上海市农业科学院 | A continuous extraction method of effective ingredients from fruitbodies of Cordyceps militaris |
| CN101307112A (en) * | 2008-07-07 | 2008-11-19 | 中国科学院微生物研究所 | Process for abstracting mycelium polysaccharide by cordyceps fermentation |
| CN101613390A (en) * | 2009-07-21 | 2009-12-30 | 贵州大学 | A kind of method of separating and purifying high-purity cordycepin |
| CN102515920A (en) * | 2011-12-23 | 2012-06-27 | 正源堂（天津）生物科技有限公司 | Culture of cordyceps militaris and preparation method of oral cordyceps militaris tablet |
-
2014
- 2014-01-27 CN CN201410040147.3A patent/CN103784481B/en not_active Expired - Fee Related
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1115671A (en) * | 1994-07-25 | 1996-01-31 | 林清渊 | Active component of cordyceps sinensis and its separation method |
| CN101007025A (en) * | 2006-01-24 | 2007-08-01 | 上海市农业科学院 | A continuous extraction method of effective ingredients from fruitbodies of Cordyceps militaris |
| CN101307112A (en) * | 2008-07-07 | 2008-11-19 | 中国科学院微生物研究所 | Process for abstracting mycelium polysaccharide by cordyceps fermentation |
| CN101613390A (en) * | 2009-07-21 | 2009-12-30 | 贵州大学 | A kind of method of separating and purifying high-purity cordycepin |
| CN102515920A (en) * | 2011-12-23 | 2012-06-27 | 正源堂（天津）生物科技有限公司 | Culture of cordyceps militaris and preparation method of oral cordyceps militaris tablet |
Non-Patent Citations (1)
| Title |
|---|
| 陈伟等: "反相高效液相色谱法分离和制备虫草素的方法研究", 《上海农业学报》, vol. 23, no. 1, 31 December 2007 (2007-12-31), pages 59 - 61 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105055428A (en) * | 2015-09-14 | 2015-11-18 | 广州普立森生物科技有限公司 | Application of peroxy-ergosterol in preparation of medicament for treating primary liver cancer |
| CN105380994A (en) * | 2015-12-09 | 2016-03-09 | 正源堂（天津）生物科技有限公司 | Extraction method and application of Nux Vomica antitumor active components |
| CN111329871A (en) * | 2020-03-13 | 2020-06-26 | 贵州贵安精准医学研究院股份有限公司 | Preparation method and application of product of cordyceps militaris for preventing and treating liver cancer |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103784481B (en) | 2016-06-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103816296B (en) | Callicarpa total glycoside extract and preparation method and application thereof | |
| CN103800388B (en) | A kind of preparation method of Armillaria luteo-virens antioxidant activity component and application thereof | |
| CN109453260A (en) | The extracting method and its application of tobacco antitumor component | |
| CN103751225B (en) | The extracting method of Cordyceps militaris (L.) Link. antitumor component and application thereof | |
| CN103494844B (en) | Yellow mushroom standardized component manufacturing method and application of components to treatment of liver cancer | |
| CN103494843B (en) | Yellow mushroom standardized component manufacturing method and application of components to treatment of lung cancer | |
| CN106892889B (en) | A kind of China's propolis flavone extract and preparation method and application | |
| CN103784481B (en) | A kind of method and application thereof extracting antitumor component from Cordyceps militaris (L.) Link. | |
| CN103800385A (en) | Method for extracting cordycepin component from Cordyceps militaris and application of cordycepin component | |
| CN103784480B (en) | The preparation method of Armillaria luteo-virens antioxidant activity component and application thereof | |
| CN103751224B (en) | Method and the application thereof of antitumor component is extracted from Cordyceps militaris (L.) Link. | |
| CN103191143B (en) | New application of cardiac glycoside compound | |
| CN109929006B (en) | Extraction method and application of ergosterol peroxide in pleurotus ferulae | |
| CN107365284A (en) | A kind of method that taxol is extracted from Chinese yew | |
| CN103623066B (en) | Corydalis impatiens total alkaloid extractive for preparing anti-cancer drugs and application thereof | |
| CN103169752A (en) | Semen momordicae extractive as well as preparation method and use thereof | |
| CN109589340B (en) | Application of mole cricket extract in preparing medicine for treating breast cancer with three yin | |
| CN108558975B (en) | 12 beta-hydroxy-androstane 4, 14-diene-16-ketone compound and application thereof | |
| CN105434479A (en) | Method for extracting antineoplastic active component from Armillaria luteo-virens and application thereof | |
| CN105693804B (en) | The method and its application of ergosterol are extracted from Armillaria luteo-virens | |
| CN106606616B (en) | Typhonium giganteum antitumor active part and preparation method and application thereof | |
| CN105687254A (en) | A method of extracting anti-lung-cancer active components from armillaria luteo-virens and applications of the active components | |
| CN105601603B (en) | The extracting method of genistein monomeric compound and its application in Armillaria luteo-virens | |
| CN105693518B (en) | The method and its application of dibutyl phthalate are extracted from trigone | |
| CN105687253A (en) | A method of extracting anti-liver-cancer active components from armillaria luteo-virens and applications of the active components |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20170414 Address after: 550025 Guizhou Province in the New District of Guizhou security comprehensive security zone Patentee after: ACADEMY OF PRECISION MEDICINE, GUIAN, GUIZHOU CO.,LTD. Address before: 300457 Tianjin international economic and Technological Development Zone, Binhai New Area, Tianjin Dongting Road, No. 220, Tianjin international joint Academy of biological medicine experimental building N511 Patentee before: ZHENGYUANTANG (TIANJIN) BIOTECHNOLOGY CO.,LTD. |
|
| CP01 | Change in the name or title of a patent holder | ||
| CP01 | Change in the name or title of a patent holder |
Address after: 550025 Guizhou Province in the New District of Guizhou security comprehensive security zone Patentee after: Guizhou Gui'an precision Medicine Co.,Ltd. Address before: 550025 Guizhou Province in the New District of Guizhou security comprehensive security zone Patentee before: ACADEMY OF PRECISION MEDICINE, GUIAN, GUIZHOU Co.,Ltd. |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20160601 |